Skip to main content

Table 2 One-year IRs – excluding patients with one-year prevalence

From: Characterising complex health needs and the use of preventive therapies in the older population: a population-based cohort analysis of UK primary care and hospital linked data

 

Bisphosphonates

N

PY

IR (95% CI)

Hospitalisation cohort

2233

69,984.6

31.91 (30.6, 33.2)

Frailty cohort

2441

85,996.6

28.39 (27.3, 29.5)

Polypharmacy cohort

2477

87269.8

28.38 (27.3, 29.5)

Overlap group

780

19,081.4

40.88 (38.0, 43.8)

Background population

2604

253,071.6

10.29 (9.9, 10.7)

 

Statins

N

PY

IR (95% CI)

Hospitalisation cohort

2472

39,902.3

61.95 (59.5, 64.4)

Frailty cohort

2520

38,216.8

65.94 (63.4, 68.5)

Polypharmacy cohort

2327

36515.6

63.73 (61.1, 66.3)

Overlap group

551

8115.8

67.89 (62.2, 73.6)

Background population

8425

177,430.1

47.48 (46.5, 48.5)

 

Anti-hypertensives

N

PY

IR (95% CI)

Hospitalisation cohort

2793

21,610.1

129.25 (124.5, 134.0)

Frailty cohort

2400

15,449.0

155.35 (149.1, 161.6)

Polypharmacy cohort

1972

12759.6

154.55 (147.7, 161.4)

Overlap group

491

2481.901

197.83 (180.3, 215.3)

Background population

9622

131,709.3

73.06 (71.6, 74.5)

  1. N Number of incident users, PY person years, IR incidence rate
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us